Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HEPLISAV-B QUARTERLY NET PRODUCT REVENUE OF $90 MILLION, A 13% YOY INCREASE; R EITERATES FULL YEAR 2025 HEPLISAV-B NET PRODUCT REVENUE GUIDANCE RANGE OF $315 TO $325 MILLION BOARD OF DIRECTORS AUTHORIZES NEW $100 MILLION SHARE REPURCHASE PROGRAM POSITIVETOPLINE PHASE 1/2 SHINGLES VACCINE TRIAL DATA PRESENTED IN LATE-BREAKER SESSION AT IDWEEK ENTERS EXCLUSIVE LICENSE AGREEMENT FORVAXART'S NOVEL ORAL COVID-19 VACCINE PROGRAM, EXPANDING PIPELINE OPPORTUNITIES CONFERENCE CALL TODAY AT 4:30 P.M. ET/1:30 P.M.

DYNAVAX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND ANNOUNCES NEW $100 MILLION SHARE REPURCHASE PROGRAM

COLLABORATION POSITIONED TO LEVERAGE VAXART'S ORAL VACCINE PLATFORM AND DYNAVAX'S COMMERCIAL EXPERIENCE TO ADDRESS THE LONG-TERM NEED FOR EASILY ADMINISTERED COVID-19 VACCINE OPTIONS VAXART TO CONTINUE LEADING AND FUNDING DEVELOPMENT THROUGH PHASE 2B COMPLETION AND END OF PHASE 2 MEETING WITH FDA ; DYNAVAX TO RECEIVE EXCLUSIVE, WORLDWIDE LICENSE AND RIGHT TO ASSUME RESPONSIBILITY FOR CONTINUED CLINICAL DEVELOPMENT AND COMMERCIALIZATION FOLLOWING PHASE 2B CLINICAL DEVELOPMENT VAXART WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND A $5 MILLION EQUITY INVESTMENT FROM DYNAVAX, ALONG WITH ADDITIONAL POTENTIAL MILESTONE-BASED PAYMENTS AND ROYALTIES CONTINGENT ON DYNAVAX ADVANCING THE PROGRAM POST-PHASE 2B DATA READOUT EMERYVILLE, CALIF.AND SOUTH SAN FRANCISCO, CALIF.

DYNAVAX ENTERS EXCLUSIVE LICENSE AGREEMENT FOR VAXART'S NOVEL ORAL COVID-19 VACCINE PROGRAM

EMERYVILLE, CALIF. , OCT. 22, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, WILL REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 5, 2025, AFTER THE U.S. FINANCIAL MARKETS CLOSE.

DYNAVAX TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 5, 2025

Z-1018 DEMONSTRATES COMPARABLE ANTIBODY AND CD4+ T-CELL RESPONSES TO SHINGRIXWITH A FAVORABLE TOLERABILITY PROFILE NEWLY PRESENTED DATA OUTLINE ROBUST POLYFUNCTIONAL CD4+ T-CELL RESPONSES IN Z-1018 ARMS COMPANY INITIATES PART 2 OF PHASE 1/2 HEAD-TO-HEAD VERSUS SHINGRIX IN ADULTS 70 YEARS AND OLDER EMERYVILLE, CALIF. , OCT. 21, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION(NASDAQ: DVAX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY PRESENTED POSITIVE TOPLINE DATA FROM PART 1 OF ITS RANDOMIZED, OBSERVER-BLINDED, ACTIVE-CONTROLLED PHASE 1/2 CLINICAL TRIAL OF Z-1018, THE COMPANY'S NOVEL SHINGLES VACCINE CANDIDATE, IN A LATE-BREAKER SESSION AT IDWEEK 2025.

DYNAVAX PRESENTS POSITIVE TOPLINE DATA FROM PART 1 OF PHASE 1/2 TRIAL FOR SHINGLES VACCINE CANDIDATE AT IDWEEK 2025 AND ANNOUNCES INITIATION OF PART 2 OF TRIAL

EMERYVILLE, CALIF. , AUG. 27, 2025 /PRNEWSWIRE/ --DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE ON WEDNESDAY, SEPTEMBER 3RD AT 4:30 P.M.

DYNAVAX TO PARTICIPATE IN THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

AT ALL DOSES AND FORMULATIONS EVALUATED IN PART 1 OF THE TRIAL, Z-1018 WAS WELL-TOLERATED AND DEMONSTRATED A FAVORABLE TOLERABILITY PROFILE, INCLUDING LOWER SOLICITED LOCAL AND SYSTEMIC POST-INJECTION REACTIONS, VERSUS SHINGRIX Z-1018 DEMONSTRATED ROBUST IMMUNE RESPONSES IN ALL DOSE ARMS, INCLUDING A 100% HUMORAL VACCINE RESPONSE RATE AT THE DOSE SELECTED FOR ADVANCEMENT, WITH COMPARABLE IMMUNOGENICITY TO SHINGRIX DYNAVAX SELECTS THE OPTIMAL DOSE OF Z-1018 FOR ADVANCEMENT TO PART 2 OF PHASE 1/2 TRIAL IN ADULTS 70 YEARS OF AGE AND OLDER, EXPECTED TO INITIATE IN 2H 2025 EMERYVILLE, CALIF. , AUG. 21, 2025 /PRNEWSWIRE/ --DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM PART 1 OF ITS RANDOMIZED, OBSERVER-BLINDED, AND ACTIVE-CONTROLLED PHASE 1/2 CLINICAL TRIAL OF Z-1018,THE COMPANY'S NOVEL SHINGLES VACCINE CANDIDATE, HEAD-TO-HEAD VERSUS SHINGRIX IN PARTICIPANTS AGED 50 TO 69 YEARS.

DYNAVAX ANNOUNCES POSITIVE TOPLINE PHASE 1/2 RESULTS SUPPORTING POTENTIAL BEST-IN-CLASS SHINGLES VACCINE PROFILE

RECORDHEPLISAV-B QUARTERLY NET PRODUCT REVENUE OF $92 MILLION, REPRESENTING 31% YEAR-OVER-YEAR GROWTH REFINES FULL YEAR 2025HEPLISAV-B NET PRODUCT REVENUE GUIDANCE RANGE TO $315 TO $325 MILLION, FROM $305 TO $325 MILLION TOP-LINE RESULTS IN PART 1 OF PHASE 1/2 SHINGLES VACCINE TRIAL EXPECTED IN AUGUST 2025 COMPLETED DOSING IN PART 1 OF PHASE 1/2 TRIAL OF PANDEMIC INFLUENZA ADJUVANT PROGRAM CONFERENCE CALL TODAY AT 4:30 P.M. ET/1:30 P.M.

DYNAVAX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

EMERYVILLE, CALIF. , JULY 29, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, AUGUST 7, 2025, AFTER THE U.S. FINANCIAL MARKETS CLOSE.

DYNAVAX TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 7, 2025

EMERYVILLE, CALIF. , JUNE 11, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION(NASDAQ: DVAX) ("DYNAVAX" OR THE "COMPANY"),A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY ANNOUNCED THAT, BASED ON THE PRELIMINARY VOTE COUNT PROVIDED BY ITS PROXY SOLICITOR FOLLOWING THE COMPANY'S 2025 ANNUAL MEETING OF STOCKHOLDERS ("ANNUAL MEETING"), DYNAVAX STOCKHOLDERS HAVE VOTED TO ELECT ALL FOUR OF ITS DIRECTOR NOMINEES  BRENT MACGREGOR, SCOTT MYERS, LAUREN SILVERNAIL AND ELAINE SUN  TO THE COMPANY'S BOARD OF DIRECTORS.

DYNAVAX STOCKHOLDERS ELECT ALL DYNAVAX DIRECTOR NOMINEES AT 2025 ANNUAL MEETING

GREENWICH, CONN.--(BUSINESS WIRE)--DEEP TRACK CAPITAL, LP, (TOGETHER WITH ITS AFFILIATES, DEEP TRACK OR WE), ONE OF THE LARGEST SHAREHOLDERS OF DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX) (DYNAVAX, DVAX OR THE COMPANY), WITH OWNERSHIP OF APPROXIMATELY 14.82% OF THE COMPANY'S OUTSTANDING SHARES, TODAY ISSUED A LETTER TO SHAREHOLDERS DETAILING THE BENEFITS OF ELECTING DEEP TRACK'S FOUR NOMINEES  BRETT ERKMAN, JEFFREY FARROW, MICHAEL MULLETTE AND DONALD SANTEL  TO THE BOARD OF DIRE.

DEEP TRACK CAPITAL SENDS LETTER TO DYNAVAX TECHNOLOGIES SHAREHOLDERS OFFERING FINAL PERSPECTIVES ON WHY CHANGE IS NEEDED IN THE BOARDROOM

DYNAVAX'S STRATEGY IS DELIVERING SIGNIFICANT LONG-TERM STOCKHOLDER VALUE DYNAVAX'S NOMINEES ARE VASTLY SUPERIOR TO DEEP TRACK'S CANDIDATES ACROSS EVERY CRITICAL AREA FOLLOW RECOMMENDATIONS OF PROXY ADVISORY FIRMS ISS AND EGAN-JONES AND VOTE "FOR" ALL FOUR OFDYNAVAX'S DIRECTOR NOMINEES ON THE GOLD PROXY CARD TODAY EMERYVILLE, CALIF. , JUNE 9, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION(NASDAQ: DVAX) ("DYNAVAX" OR THE "COMPANY"), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY ISSUED THE FOLLOWING STATEMENT REITERATING TO STOCKHOLDERS ITS RECOMMENDATION TO VOTE "FOR" ALL FOUR OF DYNAVAX'S HIGHLY QUALIFIED DIRECTORS STANDING FOR ELECTION  BRENT MACGREGOR, SCOTT MYERS, LAUREN SILVERNAIL AND ELAINE SUN  AT THE COMPANY'S UPCOMING ANNUAL MEETING OF STOCKHOLDERS ON JUNE 11, 2025 (THE "2025 ANNUAL MEETING").

DYNAVAX URGES STOCKHOLDERS TO SUPPORT ITS DIRECTOR NOMINEES AT JUNE 11 ANNUAL MEETING

DYNAVAX IS ALREADY DELIVERING SIGNIFICANT LONG TERM STOCKHOLDER VALUE THROUGH EXECUTION OF CURRENT STRATEGY OVERSEEN BY BOARD; DEEP TRACK'S INFERIOR SHORT-TERM PLAN AND NOMINEES ARE NOT IN THE BEST INTERESTS OF ALL STOCKHOLDERS GLASS LEWIS' RECOMMENDATION RECOGNIZES THE SIGNIFICANT STOCKHOLDER VALUE CREATION AND DIFFERENTIATED CAPITAL RETURN OVERSEEN BY THE DYNAVAX BOARD REITERATES ISS AND EGAN JONES RECOMMENDATIONS THAT STOCKHOLDERS SUPPORT ALL DYNAVAX NOMINEES AND DEEP TRACK BOARD REPRESENTATION IS NOT WARRANTED URGES STOCKHOLDERS TO VOTE "FOR" ALL FOUR OF DYNAVAX'S HIGHLY QUALIFIED DIRECTOR NOMINEES ON THE GOLD PROXY CARD TODAY EMERYVILLE, CALIF. , JUNE 4, 2025 /PRNEWSWIRE/ -- DYNAVAX TECHNOLOGIES CORPORATION (NASDAQ: DVAX) ("DYNAVAX" OR THE "COMPANY"), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING INNOVATIVE VACCINES, TODAY COMMENTED ON A REPORT PUBLISHED BY GLASS, LEWIS & CO. ("GLASS LEWIS") IN CONNECTION WITH THE ELECTION OF THE COMPANY'S DIRECTOR NOMINEES  BRENT MACGREGOR, SCOTT MYERS, LAUREN SILVERNAIL AND ELAINE SUN  AT ITS ANNUAL MEETING OF STOCKHOLDERS ON JUNE 11, 2025 (THE "2025 ANNUAL MEETING"): WE STRONGLY DISAGREE WITH GLASS LEWIS' RECOMMENDATION AGAINST TWO OF OUR HIGHLY QUALIFIED DIRECTORS.

Dynavax Technologies Corporation

DVAX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Dynavax Technologies Corporation

DVAX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DVAX